Pittman Scott M. - 23 Jan 2026 Form 4 Insider Report for Nuo Therapeutics, Inc. (AURX)

Role
Director, 10%+ Owner
Signature
/s/ David Jorden, attorney-in-fact
Issuer symbol
AURX
Transactions as of
23 Jan 2026
Net transactions value
+$111,474
Form type
4
Filing time
26 Jan 2026, 18:44:05 UTC
Previous filing
01 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Pittman Scott M. Director, 10%+ Owner C/O NUO THERAPEUTICS, INC., 8285 EL RIO, SUITE190, HOUSTON /s/ David Jorden, attorney-in-fact 26 Jan 2026 0001674752

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURX Commitment Warrants (right to buy) Award $3,075 +2,050 $1.50 0 23 Jan 2026 Common Stock 2,050 $1.50 Direct
transaction AURX Origination Initial Warrants (right to buy) Award $2,000 +1,333 $1.50 0 23 Jan 2026 Common Stock 1,333 $1.50 Direct
transaction AURX Capital Initial Warrants (right to buy) Award $40,000 +26,667 $1.50 0 23 Jan 2026 Common Stock 26,667 $1.50 Direct
transaction AURX Origination Second Warrants (right to buy) Award $2,625 +1,750 $1.50 0 23 Jan 2026 Common Stock 1,750 $1.50 Direct F1
transaction AURX Capital Second Warrants (right to buy) Award $52,500 +35,000 $1.50 0 23 Jan 2026 Common Stock 35,000 $1.50 Direct F1
transaction AURX Prepayment Warrants (right to buy) Award $11,274 +7,516 $1.50 0 23 Jan 2026 Common Stock 7,516 $1.50 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Will vest (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan and Security Agreement dated January 21, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement").
F2 Will vest (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement.
F3 Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement. The Board of Directors of Issuer and Non-Employee Directors approved the Loan Agreement and issuance of warrants and shares of Common Stock issuable thereunder